Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study

New results follow success of BMS’ Breyanzi in the same patient population and setting

- PMLiVE

Study finds mixed vaccine schedules provide strong immune response against COVID-19

And AZ's Vaxzevria COVID-19 vaccine shows strong immune responses following a delayed second dose

AZ appoints Susan Galbraith as executive vice president, oncology R&D

Galbraith’s appointment into the role follows the passing of José Baselga earlier this year

- PMLiVE

Mental well-being is for life, not just awareness week

Helping people identify any issues that may be affecting their mental well-being is a great first step

- PMLiVE

Breakthrough therapy designated for Lilly’s investigational Alzheimer’s drug donanemab

The BTD is based on data from the phase 2 TRAILBLAZER-ALZ study in early symptomatic Alzheimer's patients

- PMLiVE

Understanding the authentic patient experience can redefine the success of your clinical trial before you design it

. Su contributes our experience are Origins that there is a willingness within the Pharmaceutical Industry to change attitudes towards clinical trial populations – making them less about academic and...

Origins – The Patient Focused Specialists

- PMLiVE

Lilly showcases tirzepatide type 2 diabetes data at ADA 2021

Company is planning to submit the full data package for tirzepatide to regulatory authorities by the end of 2021

- PMLiVE

Stick or twist? Looking at the patient experience as we emerge from the COVID pandemic

The pandemic has given us a glimpse (actually, more of a very long look) at an alternative way of receiving healthcare and engaging with the NHS. And that alternative fits...

Say Communications

- PMLiVE

Staying in the loop – six principles for impactful integrated communications

by James Hadfield

- PMLiVE

Healthcare communications – adapting to ‘the new normal’

by Diane Wass and Ken Deutsch

- PMLiVE

Novo Nordisk reveals positive results at ADA 2021 for higher-dose Ozempic in type 2 diabetes

Ozempic 2 mg demonstrated a 2.2% reduction in blood sugar compared with a 1.9% reduction for those receiving Ozempic 1 mg

- PMLiVE

Stick or Twist? Healthcare brands in a (post) COVID-19 world

How have our perceptions of healthcare brands and our purchasing habits changed during the COVID-19 pandemic?

Say Communications

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links